Aurobindo Pharma reappoints Mangalam Ramasubramanian Kumar as Independent Director
- Board approved re-appointment of Mangalam Ramasubramanian Kumar as Independent Director
- Second five-year term effective April 1, 2027, subject to shareholder approval
- Kumar served as Chairman of LIC of India from March 2019 to March 2023
- He is not related to any other Director or Key Managerial Personnel of the company

*this image is generated using AI for illustrative purposes only.
Aurobindo Pharma has approved the re-appointment of Mangalam Ramasubramanian Kumar as a Non-executive and Independent Director for a second term of five years. The appointment is effective from April 1, 2027, following the completion of his current term on March 31, 2027.
The decision was taken by the Board of Directors during a meeting held on November 4, 2026. The move is based on the recommendation of the Nomination and Remuneration Committee and remains subject to the approval of shareholders through a postal ballot.
Director profile and background
Kumar brings extensive experience from the Indian insurance and banking sectors to the Aurobindo Pharma board. He served as the Chairman of Life Insurance Corporation (LIC) of India from March 2019 to March 2023. His career at LIC spanned more than three and a half decades, beginning in 1983 as a Direct Recruit Officer.
During his tenure, he headed three zones of LIC: Southern, North Central, and Northern. He also led the Personnel Department and the Pension and Group Insurance verticals. Notably, as Non-Executive Chairman of IDBI Bank, he contributed to strategizing its turnaround from a loss-making entity to a profitable one.
Current directorships
Kumar currently holds several significant positions in the financial sector:
- Director on the Board of Cholamandalam Investment and Finance Company Limited
- Director on the Board of Aurobindo Pharma USA Inc.
- Non-executive Chairman of Bank of India
He has previously served as Non-Executive Chairman for various LIC subsidiaries, including LIC Housing Finance Ltd., LIC Pension Fund Ltd., and LIC Mutual Fund AMC Ltd. Additionally, he held directorships at ACC Ltd. and Kenindia Assurance Co. Ltd.
Governance and compliance details
The company confirmed that Kumar is not related to any Director or Key Managerial Personnel of Aurobindo Pharma. He is not debarred from holding the office of Director by any SEBI order or other authority. Under the terms of his re-appointment, he will be entitled to receive sitting fees for attending board and committee meetings, along with commission.
The re-appointment ensures continuity in independent oversight, leveraging Kumar’s deep expertise in financial management and regulatory compliance within large public sector undertakings.
Historical Stock Returns for Aurobindo Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.89% | +2.14% | +6.81% | +22.51% | +54.04% | +165.04% |
How might Kumar's recent success in turning around IDBI Bank influence Aurobindo Pharma's capital allocation strategies or debt management plans?
What specific governance improvements or risk mitigation frameworks is Aurobindo Pharma expected to implement under Kumar's continued independent oversight?
Could Kumar's dual role as Non-Executive Chairman of Bank of India and Director at Aurobindo Pharma create potential conflicts of interest regarding future financing deals?


































